Immunovant (NASDAQ: IMVT) is expected to announce its third-quarter earnings for 2026 before the market opens on February 6, 2026. Analysts project the company will report a loss of ($0.71) per share for the quarter. The earnings call is scheduled for 8:00 AM ET, and interested parties can access the latest updates on the company’s earnings results page.
In its previous earnings announcement on November 10, 2025, Immunovant reported a loss of ($0.73) per share, which fell short of analysts’ consensus estimates of ($0.72) by ($0.01). This represented a slight improvement from the same quarter the previous year, when the company posted a loss of ($0.74) per share. For the current fiscal year, analysts anticipate an average loss of ($3) per share, with similar expectations for the upcoming fiscal year.
Market Performance and Analyst Insights
On Thursday, shares of Immunovant opened at $25.15, reflecting a decline of 2.5%. The company holds a market capitalization of $4.41 billion and maintains a price-to-earnings ratio of -8.86. The stock has a beta of 0.54, indicating lower volatility compared to the market. Currently, Immunovant’s fifty-day simple moving average is $25.55, while the 200-day simple moving average stands at $20.66. Over the past year, the stock has fluctuated between a low of $12.72 and a high of $27.80.
Recent insider trading activity has also garnered attention. On December 18, 2025, Tuyl Christopher Van, an insider at Immunovant, sold 10,813 shares at an average price of $26.91, totaling $290,977.83. Following this transaction, Van retained 149,930 shares, valued at approximately $4.03 million, reflecting a 6.73% decrease in their position. The sale was publicly disclosed in a filing with the SEC.
Additionally, Director Andrew J. Fromkin sold 22,249 shares on December 1, 2025, at an average price of $23.25, resulting in a total transaction of $517,289.25. After this sale, Fromkin holds 85,852 shares worth about $1.996 million, marking a 20.58% decrease in their holdings. Over the past 90 days, insiders have sold a total of 63,868 shares, valued at $1.54 million, with insider ownership now at 1.80% of the company’s stock.
Institutional Movements and Company Profile
In terms of institutional activity, hedge funds and other investors have recently altered their stakes in Immunovant. Prelude Capital Management LLC established a new position valued at approximately $672,000 during the third quarter. Algert Global LLC also acquired a new stake worth $563,000. Creative Planning increased its holdings by 8.9%, now owning 38,503 shares valued at $621,000 after acquiring an additional 3,135 shares. Other notable movements include LMR Partners LLP, which purchased a stake valued at $401,000, and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., which boosted its investment by 4.1% during the second quarter. Currently, institutional investors hold approximately 47.08% of Immunovant’s stock.
Immunovant Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative monoclonal antibody therapies targeting the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant aims to reduce pathogenic immunoglobulin G (IgG) antibodies, which are central to the pathology of conditions such as myasthenia gravis and immune thrombocytopenia. The company’s primary asset, efgartigimod, is engineered to selectively bind to FcRn, promoting the degradation of circulating IgG.
For further updates, stakeholders can subscribe to daily summaries and news from MarketBeat.com regarding Immunovant and related companies.
